The team of entrepreneurial scientists at Chimagen aims to deliver innovative medicine to address the unmet medical needs in the area of oncology. The company has extensive experience in the therapeutic monoclonal antibody industry, from early discovery to clinical studies. They work closely with immune-oncology scientists and CMC experts, and are devoted to reset the immune system to kill cancer cells with its new generation of antibodies. Several molecules are currently being constructed and under evaluation in their preclinical and clinical phase.